The AACR Annual Meeting is the premier event for presenting cutting-edge cancer research covering the spectrum of science from the bench to the clinic. The Annual Meeting 2013 reinforced the AACR’s long-standing commitment to highlighting the best science-based clinical research. Seventeen clinical trials were featured in four trials sessions, and there were 21 trials presented in four minisymposia. Seven poster sessions offered clinical researchers additional opportunities to present their research.
In 2014, there will be numerous opportunities to showcase cutting-edge clinical research including the Clinical Symposia, which offer a unique presentation format. Clinical trials selected for oral presentation will consist of two separate talks: one featuring the trial data and one explaining the science informing the development of the novel agent and/or diagnostic and the clinical trial. In addition to providing the scientific context for the clinical studies, this format provides increased opportunities for presentation. Any phase I, II, or III clinical trials abstracts submitted for either the regular or the late-breaking deadline to the Clinical Trials (CT) category will be considered by the Program Committee for oral presentation in one of these clinical trials-focused sessions.
PLACEHOLDER ABSTRACTS FOR CLINICAL TRIALS
In an effort to ensure that the latest and most exciting new data from clinical trials are presented at the Annual Meeting 2014, the AACR has implemented a special policy for submission of late-breaking abstracts. A placeholder abstract may be submitted by the late-breaking abstract deadline of January 27, 2014, for clinical trials that only have preliminary data available at the time of submission. Final results and conclusions for placeholder abstracts must be submitted by February 28, 2014. To be eligible for consideration, the following guidelines must be strictly followed:
- Abbreviated abstracts must be submitted by the late-breaking abstract submission deadline of January 27, 2014, and must also comply with the rules specified for their submission.
- A placeholder abstract category must be selected in the Online Abstract Submission System:
- PL01: Phase I Adult Clinical Trials
- PL02: Phase II Adult Clinical Trials
- PL03: Phase III Adult Clinical Trials
- PL04: Phase I, II, or III Clinical Trials in Pediatric Cancer
- PL05: Phase I, II, or III Clinical Trials in the Elderly
- PL06: Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations
- PL07: Clinical Trials Using Radiation
- Abstracts must include the following information:
- Objectives of the study
- Preliminary data or an indication of the type of results anticipated. (This is especially applicable to clinical trials that are about to be closed.)
- Completed abstracts including all data—that is, results and conclusions—must be submitted by the final deadline of February 28, 2014.
The submission of abstracts in accordance with these guidelines does not guarantee acceptance by the special subcommittee. All late-breaking and placeholder abstracts must be submitted online. Complete instructions for preparing and submitting these abstracts will be available in January 2014.
CLINICAL TRIALS IN PROGRESS POSTER SESSION
Abstracts submitted to the Clinical Trials in Progress (CT8) category should summarize promising ongoing trials that have not yet yielded final results. A designated area of the poster hall will be dedicated to the presentation and discussion of abstracts accepted to this category.